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Introduction
The experience of clinical researchers
worldwide indicates that a major obstacle
to undertaking academic research is the
ever-increasing bureaucracy attached to
the process. Recent changes in research
governance were intended to ensure that
clinical trials are safe and informative.
However, the regulatory burden is now
obstructing high quality science and has
become the biggest single threat to research
carried out in academia [1]. We illustrate
here this international problem by refer-
ence to the regulations imposed by the
European Union and the incorporation of
these restrictions into UK national law
concerning Good Clinical Practice (GCP).
GCP sounds like a sensible idea that all
researchers would aspire to. However, it
used to have a technical meaning in the
pharmaceutical industry when attempting
to license new pharmacological entities with
government agencies such as the Food and
Drug Administration in the US. This
technical meaning was to follow (specifical-
ly) the International Conference on Har-
monisation (ICH) document on GCP [2],to
facilitate the conduct of multinational drug
trials sponsored by the pharmaceutical
industry. The harmonisation process was
developed over many years by the industry.
ICH GCP and the attendant regulations
apply to medicinal products for human use
only. Nonmedicinal treatments such as
psychological interventions and surgery
are exempt. There are serious concerns
that the onerous procedural requirements
for data management and documentation
stipulated by ICH are deterring academic
research where registration of a new
pharmaceutical entity is not an objective.
The rigid bureaucracy of GCP as defined
by ICH has already been recognised as an
impediment to clinical research, resulting in
an effect opposite to that originally envis-
aged [3]. The ICH guideline on GCP
provides extremely detailed instructions on
data management and reporting of trials, as
would be appropriate for drug companies
seeking to license a new pharmaceutical
entity with the relevant drug agencies. The
true purpose of GCP, based upon founda-
tions in the original Declaration of Helsinki,
is to protect patients from unethical re-
search, ensure that patients provide in-
formed consent, and to conduct all trials to
the highest possible standard. Few would
dispute the need to incorporate the highest
standards of GCP in all clinical trials, but
does full application of ICH facilitate this
goal? Unfortunately the standards of ICH
GCPhavebeenrolled outacrossEuropefor
all trials of medicinal products in humans in
a series of regulations.
Regulation in Europe
By May 2004, The European Directive
2001/ 20/ EC on clinical trials (‘‘The
Directive’’) had been adopted across the
European Union [4]. Implicit in the title of
The Directive is the implementation of
GCP and articles of The Directive include
informed consent, ethics committees, re-
porting of adverse events, and national
inspection of trials. The Directive was
incorporated into the law of the United
Kingdom in the Medicines Act [5] and is
described on the Medicines and Healthcare
Products Regulatory Agency (MHRA)
website [6]. ‘‘The conditions and principles
of GCP which apply to all clinical trials’’
are ‘‘based on’’ the ICH guideline. The
European Directive 2005/28/EC attempts
to provide more detailed guidelines on
GCP [7]. This GCP Directive instructs that
the ICH guideline on GCP should be
‘‘taken into account.’’ The content of this
directive appears advisory rather than
prescriptive. Whether it was intended for
academic clinical trials to be included is
uncertain. The Medicines Act stipulates
only the general principles section of ICH
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Summary Points
N Trial regulations are damaging noncommercial research and patients.
N The International Conference on Harmonisation (ICH) version of Good Clinical
Practice (GCP) is inapplicable to most noncommercial research.
N ICH GCP is not usually legally binding (as conceded by the regulatory
authorities in the UK).
N Other parts of the world should learn a lesson from the misguided trial
regulations that have been created in Europe.
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[5,6]. The GCP Directive states that
noncommercial research as carried out by
public bodies can ‘‘make the application of
certain of the details of good clinical
practice unnecessary or guaranteed by
other means,’’ with member states ‘‘pro-
viding for specific modalities.’’ However,
the eventual draft guidance mainly discuss-
es treatment labelling and trial documen-
tation [8].
Following the 2005 ‘‘GCP Directive,’’
the UK Medicines Act had to be amend-
ed. The first amendment (August 2006)
mainly addressed technical matters such as
document handling and payment of fees to
MHRA but with no mention of ‘‘taking
into account’’ the ICH GCP document
[9]. The second amendment (December
2006) was specifically designed to enable
trials in emergency medicine where in-
formed consent could not be obtained
from an incapacitated patient [10]. Ex-
planatory memoranda for both amend-
ments are on the MHRA website [11,12].
When queried, the MHRA clinical trials
helpline (clintrialhelpline@mhra.gsi.gov.uk)
made the following statements: ‘‘ICH is the
standard expected by the CHMP for trials
used for centralised licensing submissions’’;
‘‘ICH is only mentioned in the recital of
European Directive 2005/28/EC. The
recital is not legally binding’’; ‘‘Some
member states chose to make ICH GCP
their legal standard – the UK did not.’’
Despite this, trial centres in the UK are
being aggressively audited to ICP GCP
standards.
Damage to Noncommercial
Trials
The academic and public research
communities were alarmed at the prospect
of the directive of May 2004 [13–17].
These regulations were clearly created for
the benefit and/or regulation of the
pharmaceutical industry [18,19], and it
was inevitable that the number of non-
commercial trials would decrease [20]. It
was also anticipated that the pharmaceu-
tical industry itself would avoid the extra
costs by moving trials out of Europe and
into less developed countries [21]. The
potential problem for noncommercial
research was clearly recognised by the
MHRA, which appeared powerless to
intervene [22]. A second GCP Directive
followed and three UK laws were passed
to implement these Directives. The pro-
cess for ever-increasing bureaucracy ap-
pears to be on-going with no sign of
conclusion. In the meantime there has
been real damage to patient care across
the European Union. The EU was warned
that the directive would severely impair
trials in emergency medicine, because of
the difficulty of obtaining a legal represen-
tative to give informed consent [23]. The
problem with the directive was first
recognised in Austria [24], but applies to
the whole of Europe and was not resolved
in the UK until 2006.
Despite concerns, the amended Medi-
cines Act was duly passed in May 2004.
Were the initial concerns misplaced, and
once embedded did the new regulations
begin to work in the desired manner? The
evidence suggests not. By the end of 2005
one group in Cardiff noted that they had
‘‘almost stopped doing drug studies’’ [25],
and it was estimated that the number of
European trials submitted for grants or
ethical review had fallen by 30% to 50%
and that the proportion of noncommercial
trials was reduced from 40% to 14% [26].
Meanwhile, there does not seem to be
much harmonisation of laws across the
European Union, one of the main goals of
the whole exercise [27,28]. The ability of
European centres to compete with the
better funded US noncommercial trials
has been damaged, perhaps irreversibly.
The largest independent cancer re-
search network in Europe (EORTC) has
reported that the number of new trials
dropped from 38 in 2001, to 19 in 2004, to
seven in 2005; trial costs have increased by
85% and trial initiation was five months
slower [29,30]. Senior oncologists have
concluded that cancer patients in the
future ‘‘should be worried’’ [28]. This
report attracted letters stating that The
Directive had also led to the abandonment
of a trial to address fibromyalgia, and of a
trial of melatonin, and it was eroding the
normally very high rates of recruitment
into paediatric cancer trials (an area of
very little interest to the pharmaceutical
industry) [31–33]. There were around ten
to 20 studies in paediatric oncology
starting per annum before implementation
of The Directive, and this has now
dropped to a handful [34]. The future of
noncommercial paediatric trials in general
is in difficulty as the number of studies
‘‘will decrease dramatically in the future’’
[35]. As Mitchell notes: ‘‘For children with
cancer the effect of this directive has been
appalling’’ [36].
There was some hope that a European
Regulation that was designed to help
promote paediatric trials would help the
noncommercial sector [35]. This directive,
EU Regulation 1901/2006 ‘‘on medical
products for paediatric use’’ came into
force in January 2007 and is clearly
focussed on the pharmaceutical industry’s
ability to patent and market new treat-
ments for children [37,38]. In any case the
Paediatric Regulation insists on full com-
pliance with the Clinical Trial Directive!
There is some doubt as to the utility of this
Regulation for even industrial trials [39].
A survey of eight cancer clinical trial
centres in the UK also found that the cost
of noncommercial trials had doubled,
trials have been delayed, and staff were
demoralised in many trial centres [40].
Since funds are often collected directly
from the public by charity appeals, public
money is being spent. It always difficult to
fund clinical trials in this way, with some
of the real costs being absorbed or cross-
subsidised in department accounts. Con-
siderably more money is now required,
and only projects that are attractive to the
pharmaceutical industry are likely to
proceed. Since outcomes are often better
in patients taking part in clinical trials,
countless thousands receiving care outside
of trials are therefore having their health
damaged because of the reduced recruit-
ment into trials. This is particularly true of
areas that are of no interest to the
pharmaceutical industry.
Discussion
Drug trials initiated in academia have
similarities with conventional pharmaceu-
tical company trials but also important
differences. The primary aims of academic
trials are to improve patient care rather
than to develop new pharmacological
entities. Surely, these objectives are of
equivalent or of greater importance to
society? In the conduct of both types of
trial, GCP is important but the need for
intrusive bureaucracy to ensure harmoni-
sation is much less relevant to academic
studies usually carried out at a single site.
In the past, the pharmaceutical industry
might have sponsored such research but
The Directive makes this much less likely.
The requirements of The Directive have
dissuaded Universities from taking on this
role. Accumulating evidence suggests that
many research units and individual re-
searchers have withdrawn from noncom-
mercial randomised clinical trials altogeth-
er because of The Directive.
ICH standards are expected by phar-
maceutical companies for licensing sub-
missions. According to the MHRA (by
personal communication) the legally bind-
ing parts of the trial regulations include the
following: staff must be qualified, proce-
dures should be in place to ensure quality;
data should be accurate and verified;
patient confidentiality should be main-
tained; patient consent is documented.
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doing a professional job of doing good
quality trials. There is no mention of the
massive list of SOPs or the entire training
and auditing industry that has sprung up
around the ICH documents. We should
not forget that the GCP Directive itself
conceded that that the conditions of
noncommercial trials render the ‘‘applica-
tion of certain of the details of good
clinical practice unnecessary or guaran-
teed by other means.’’
There appears to be some room for
manoeuvre in the legislation with regard
to the interpretation of ‘‘good clinical
practice.’’ Instead of accepting each new
layer of bureaucracy the academic com-
munity should clarify these developments,
using legal advice where necessary. The
cost-effectiveness of the type of procedures
that ICH GCP generates is untested. For
example, it has been estimated that the
cost of a single ‘‘data query’’ is US$150.
Robert Califf notes that this is a ‘‘colossal
waste of money,’’ and that a more effective
and scientific method would be to use
sampling and the statistical process control
techniques that are found in other indus-
tries (such as engineering and manufac-
turing) [41]. In short, there is no evidence
that the intense bureaucracy of centralised
politically driven procedures for ICH GCP
has improved the care of trial participants
in any way.
As bureaucracy increases, the efficiency
of the trial process decreases. There is no
evidence base to support the implementa-
tion of the burden of this extra bureau-
cracy, and academics are perplexed as to
the utility of this bureaucracy. There is a
phrase for overinterpretation of regulatory
advice that is sometime used when dis-
cussing EU competition and tendering
rules called ‘‘regulatory creep.’’ Hearn
and Sullivan have pointed out that ‘‘reg-
ulatory creep’’ is being caused by overin-
terpretation of trial ‘‘guidance’’ [40].
Instead of regulatory creep in clinical
trials, we would like to see some ‘‘regula-
tory retreat’’ where academics try to
ensure that the interpretation of any rules
and procedures that are not mandated by
law are the most favourable for academic
research whilst ensuring patient safety.
Researchers funded with public money
should seek to adhere to the legal mini-
mum required to carry out research rather
than the bureaucratic maximum as sug-
gested by ICH GCP. Ideally there would
be a completely different and alternative
version of GCP for noncommercial trials,
especially those that study medications
that have been on the market for decades
and have treated millions of patients.
Of course these problems apply directly
to all trials that plan to include a European
centre. Other parts of the world now have
a new advantage for attracting clinical
research, at the expense of European
patients. A further advantage is that other
parts of the world can use Europe as a
‘‘test bed’’ to demonstrate the dreadful
problems of misguided regulation, and can
choose to avoid these difficulties if they
wish. The dangers of applying ICH GCP
to trials where it should be considered to
be inapplicable have been demonstrated in
this paper. A first step would be for
noncommercial researchers to recognise
that ICH GCP is not usually legally
binding in a particular country (e.g., the
UK). We would favour a combined tactic
of lobbying to simplify and ‘‘regulatory
retreat’’ and perhaps we could then look
forward to more ‘‘specific modality’’
exceptions for noncommercial trials in
future legislation.
Author Contributions
ICMJE criteria for authorship read and met:
ADM DIC TMM GTM. Wrote the first draft of
the paper: ADM. Contributed to the writing of
the paper: DIC TMM GTM.
References
1. Stewart PM, Stears A, Tomlinson JW, Brown MJ
(2008) Regulation – the real threat to clinical
research. BMJ 337: 1085–1087.
2. ICH Good Clinical Practice CPMP/ICH/135/
95. Available: http://www.emea.europa.eu/
pdfs/human/ich/013595en.pdf. Accessed 6 July
2009.
3. Baum M, Buchanan M, Baselga J, Cataliotti L,
Jassem J, et al. (2007) The future of breast cancer
research in danger. Eur J Can 38: 2210–2213.
4. (2001) Directive 2001/20/ EC of the European
parliamentandofthe council of 4April 2002onthe
approximation of the laws, regulations and admin-
istrative provisions of the Member States relating to
the implementation of good clinical practice in the
conduct of clinical trials on medicinal products for
human use. Official Journal of the European
Communities L121: 34–44. Available: http://ec.
europa.eu/enterprise/pharmaceuticals/eudralex/
vol-1/dir_2001_20/dir_2001_20_en.pdf. Accessed
6J u l y2 0 0 9 .
5. (2004) The Medicines for Human Use (Clinical
Trials) Regulations 2004. Available: http://www.
opsi.gov.uk/si/si2004/20041031.htm. Accessed 6
July 2009.
6. MHRA website. Available: http://www.mhra.
gov.uk/index.htm. Accessed 6 July 2009.
7. (2005) Commission Directive 2005/28/EC of 8
April 2005 laying down principles and detailed
guidelines for good clinical practice as regards
investigational medicinal products for human use,
as well as the requirements for authorisation of
the manufacturing or importation of such prod-
ucts. Official Journal of the European Commu-
nities L91: 13–19. Available: http://ec.europa.
eu/enterprise/pharmaceuticals/eudralex/vol-1/
dir_2005_28/dir_2005_28_en.pdf. Accessed 6
July 2009.
8. (2005) Draft guidance on ‘specific modalities’ for
non-commercial clinical trials referred to in
Commission Directive 2005/28/EC laying down
the principles and detailed guidelines for good clinical
practice. Available: http://ec.europa.eu/enterprise/
pharmaceuticals/pharmacos/docs/doc2006/
07_2006/guide_noncommercial_2006_07_27.pdf.
Accessed 6 July 2009.
9. (2006) Statutory Instrument 2006 No. 1928. The
Medicines for Human Use (Clinical Trials)
Amendment Regulations 2006. Available:
http://www.opsi.gov.uk/si/si2006/20061928.
htm. Accessed 6 July 2009.
10. (2006) Statutory Instrument 2006 No. 2984. The
Medicines for Human Use (Clinical Trials)
Amendment (No. 2) Regulations 2006. Available:
http://www.opsi.gov.uk/si/si2006/20062984.
htm. Accessed 6 July 2009.
11. (2006) Explanatory Memorandum to the Medicines
for Human Use (Clinical Trials) Amendment
Regulations 2006 No. 1928.Available:http://www.
opsi.gov.uk/si/em2006/uksiem_20061928_en.pdf.
Accessed 6 July 2009.
12. (2006) Explanatory Memorandum to the Medicines
for Human Use (Clinical Trials) Amendment
Regulations 2006 No. 2984.Available:http://www.
opsi.gov.uk/si/em2006/uksiem_20062984_en.pdf.
Accessed 6 July 2009.
13. Anonymous (2003) Who’s afraid of the European
Clinical Trials Directive? Lancet 361: 2167.
14. Sullivan R, Law K (2003) Cancer research UK
says… Lancet Onc 4: 718–719.
15. Morice AH (2003) The death of academic clinical
trials. Lancet 361: 1568.
16. Flavell DJ, Flavell SU, Sullivan R (2003) Euro-
pean Clinical Trials Directive: responses made to
MHRA consultation letter MLX 287. Lancet
3623: 1415.
17. Anon (2004) EU clinical trials directive: 0%
inspiration, 100% perspiration? Lancet Neur 3:
321.
18. Meunier F, Dubois N, Negrouk A, Rea LA (2003)
Throwing a wrench in the works? Lancet Onc 4:
717–718.
19. Williams N (2004) Breast cancer research and the
European Union Clinical Trials Directive. Breast
Can Res 6: 145–147.
20. Saghatchian M, Tursz T (2003) Organisation of
European Cancer Institutes says… Lancet Onc 4:
718.
21. Nundy S, Gulhati CM (2005) A new colonialism?
Conducting clinical trials in India. N Engl J Med
352: 1633–1636.
22. Woods K (2004) Implementing the European
clinical trials directive - Discussions continue in
the European Commission and the United
Kingdom. BMJ 328 7434: 240–241.
23. Singer EA, Mullner M (2002) Implications of the
EU directive on clinical trials for emergency
medicine - Many trials in emergency medicine
will not be possible. BMJ 324: 1169–1170.
24. Druml C, Singer EA (2004) The European
Directive: a further blow to science in intensive
care medicine in Austria. Inten Care Med 30:
335.
25. Hall JE, Diaz-Navarro C (2005) Living with the
European Clinical Trials Directive: one year on.
Anaesthesia 60: 949–951.
26. Bosch X (2005) Europe’s restrictive rules stran-
gling clinical research. Nat Med 11: 1260.
27. Hartmann M, Hartmann-Vareilles F (2006) The
clinical trials directive: how is it affecting Europe’s
noncommercial research? PLoS Clin Trials 1:
e13. doi:10.1371/journal.pctr.0010013.
28. Sinha G (2006) European move affects academic
trials research. J Nat Can Inst 98: 1100–1101.
PLoS Medicine | www.plosmedicine.org 3 November 2009 | Volume 6 | Issue 11 | e100013129. Hemminki A, Kellokumpu-Lehtinen PL (2006)
Harmful impact of EU clinical trials directive -
Academic clinical research in cancer seems to
have no future in Europe. BMJ 332: 501–502.
30. Rice M (2006) New data on clinical trials directive
in Europe show few favourable outcomes. J Nat
Can Inst 98: 159–160.
31. Hanning CD, Rentowl P (2006) Harmful impact
of EU clinical trials directive - Trial of alerting
drug in fibromyalgia has had to be abandoned.
BMJ 332: 666.
32. Watson M (2006) Harmful impact of EU clinical
trials directive … and so has trial of melatonin in
cancer related weight loss. BMJ 332: 666.
33. Mitchell CD (2006) Harmful impact of EU
clinical trials directive … while paediatric oncol-
ogy is being scuppered. BMJ 332: 666.
34. Cannell E (2007) Clinical Trials Directive slows
registration of paediatric studies. Lancet Onc 8:
10.
35. Welzing L, Harnischmacher U, Weyersberg A,
Roth B (2007) Consequences of Directive 2001/
20/EC for investigator-initiated trials in the
paediatric population - a field report. Eur J Ped;
166: 1169–1176.
36. Mitchell C (2007) Clinical trials in paediatric
haematology-oncology: are future successes
threatened by the EU directive on the conduct
of clinical trials? Arc Dis Child 92: 1024–1027.
37. European Parliament (2006) EU Regulation 1901/
2006. Available: http://ec.europa.eu/enterprise/
pharmaceuticals/eudralex/vol-1/reg_2006_1901/
reg_2006_1901_en.pdf. Accessed 6 July 2009.
38. Lehmann B (2008) Regulation (EC) No 1901/
2006 on medicinal products for paediatric use &
clinical research in vulnerable populations. Child
Adolesc Psychiatry Ment Health 2: 37.
39. Permanand G, Mossialos E, McKee M (2007)
The EU’s new paediatric medicines legislation:
serving children’s needs? Arc Dis Child 92:
808–811.
40. Hearn J, Sullivan R (2007) The impact of the
‘Clinical Trials’ directive on the cost and conduct
of non-commercial cancer trials in the UK.
Eur J Can 43: 8–13.
41. Califf RM (2007) Clinical trials bureaucracy:
unintended consequences of well-intentioned
policy. Clin Trials 6: 496–502.
PLoS Medicine | www.plosmedicine.org 4 November 2009 | Volume 6 | Issue 11 | e1000131